A retrospective cohort study evaluating the relationship between the severity of vitamin D deficiency and the clinical and biochemical presentations of patients with primary hyperparathyroidism (PHPT)

2019 ◽  
Author(s):  
Sherwin Criseno ◽  
Jasmine Virk ◽  
Peter Nightingale ◽  
Tarekegn Geberhiwot ◽  
Neil Gittoes
Keyword(s):  
Vitamin D ◽  
Cohort Study ◽  
Primary Hyperparathyroidism ◽  
Vitamin D Deficiency ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
The Relationship

scholarly journals Alfacalcidol improves the growth velocity in children with vitamin D deficiency/insufficiency: A single center retrospective cohort study

PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0247886
Author(s):  
Satoshi Miyagaki ◽  
Mihoko Yamaguchi ◽  
Takeshi Ota ◽  
Yasuhiro Kawabe ◽  
Hidechika Morimoto ◽  
...  
Keyword(s):  
Vitamin D ◽  
Cohort Study ◽  
Replacement Therapy ◽  
Vitamin D Deficiency ◽  
Growth Velocity ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Pediatric Patients ◽  
Standard Deviation Score ◽  
Poor Growth

Objectives To investigate the growth velocity-improving effects of vitamin D replacement therapy in pediatric patients diagnosed with vitamin D deficiency and insufficiency. Study design A retrospective cohort study was conducted in 34 pediatric patients diagnosed with vitamin D deficiency/insufficiency. Based on the clinical findings, the subjects were divided into two groups: a bowed leg (BL) group and a non-bowed leg (non-BL) group. After the initiation of alfacalcidol, the standard deviation score (SDS) of their heights, weights and growth velocities in each group were monitored. Results The median age at the first visit was significantly lesser in the BL group (1.58 years old [interquartile range (IQR): 1.33, 2.17]) than that in the non-BL group (3.00 years old [IQR: 2.33, 3.67]). On the contrary, the SDS for height was significantly lower in the non-BL group (-2.27 [IQR: -2.63, -1.94]) than that in the BL group (-1.37 [IQR: -1.91, -1.07]). One-year treatment with alfacalcidol showed significant improvements in both height SDSs and growth velocity SDSs not only in the BL group but also in the non-BL group. Conclusions The current study revealed that vitamin D replacement therapy improved the growth rate in children with vitamin D deficiency/insufficiency, regardless of the presence of BL. This study emphasizes the importance of assessing the vitamin D status in children with poor growth rates and suggests that alfacalcidol could be a valid option for the treatment of short stature.

scholarly journals Preoperative vitamin D deficiency is a risk factor for postoperative hypocalcemia in patients undergoing total thyroidectomy: retrospective cohort study

2019 ◽  
Vol 137 (3) ◽  
pp. 241-247
Author(s):  
Genival Barbosa de Carvalho ◽  
Lina Restrepo Giraldo ◽  
Renan Bezerra Lira ◽  
Isabela Bergh Martins Macambira ◽  
Marcel Adalid Tapia ◽  
...  
Keyword(s):  
Vitamin D ◽  
Risk Factor ◽  
Cohort Study ◽  
Total Thyroidectomy ◽  
Vitamin D Deficiency ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Postoperative Hypocalcemia

scholarly journals Retrospective cohort study of the relationship between systolic blood pressure variability and multiple sclerosis disability

BMJ Open ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. e034355 ◽  
Author(s):  
Myla D Goldman ◽  
Seulgi Min ◽  
Jennifer M Lobo ◽  
Min-Woong Sohn
Keyword(s):  
Multiple Sclerosis ◽  
Blood Pressure ◽  
Cohort Study ◽  
Systolic Blood Pressure ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Outcome Measure ◽  
Patient Reported Outcome ◽  
Patient Reported ◽  
The Relationship

ObjectiveTo examine the relationship between visit-to-visit systolic blood pressure (SBP) variability and patient-reported outcome measure of disability in multiple sclerosis (MS) patients.DesignA retrospective cohort study of individuals with MS who completed a patient-determined disease steps (PDDS) scale between 2011 and 2015 at an MS specialty clinic.ParticipantsIndividuals with MS for whom both a completed PDDS scale and ≥3 SBP measures within the prior 12 months of the survey were available.Main outcome measureParticipants were grouped into three classes of disability (no or mild (PDDS 0–1), moderate (2–3), severe (4–7)). SBP variability was calculated as within-subject SD using all SBP measures taken during the past 12 months. SBP variability was analysed by Tertile groups.ResultsNinety-two subjects were included in this analysis. Mean PDDS score was 2.22±1.89. Compared with subjects in Tertile 1 (lowest variability), the odds of being in a higher disability group was 3.5 times higher (OR=3.48; 95% CI: 1.08 to 11.25; p=0.037) in Tertile 2 and 5.2 times higher (OR=5.19; 95% CI: 1.53 to 17.61; p=0.008) in Tertile 3 (highest variability), independent of mean SBP, age, sex, race/ethnicity, body mass index and comorbidities (p for trend=0.008). Mean PDDS scores were 1.52±1.18 in Tertile 1, 2.73±1.02 in Tertile 2 and 2.42±0.89 in Tertile 3 after adjusting for the same covariates.ConclusionsOur results show a significant gradient relationship between SBP variability and MS-related disability. More research is needed to determine the underlying pathophysiological relationship between SBP variability and MS disability progression.

Sign in / Sign up

Export Citation Format

Share Document